These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9006092)
1. Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis. Farinati F; Herszényi L; Plebani M; Carraro P; De Paoli M; Cardin R; Roveroni G; Rugge M; Nitti D; Grigioni WF; D'Errico A; Naccarato R Carcinogenesis; 1996 Dec; 17(12):2581-7. PubMed ID: 9006092 [TBL] [Abstract][Full Text] [Related]
2. Cysteine and serine proteases in gastric cancer. Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115 [TBL] [Abstract][Full Text] [Related]
3. The role of cysteine and serine proteases in colorectal carcinoma. Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696 [TBL] [Abstract][Full Text] [Related]
4. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer. Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803 [TBL] [Abstract][Full Text] [Related]
5. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer]. Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782 [TBL] [Abstract][Full Text] [Related]
6. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Levicar N; Kos J; Blejec A; Golouh R; Vrhovec I; Frkovic-Grazio S; Lah TT Cancer Detect Prev; 2002; 26(1):42-9. PubMed ID: 12088202 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Harbeck N; Alt U; Berger U; Krüger A; Thomssen C; Jänicke F; Höfler H; Kates RE; Schmitt M Clin Cancer Res; 2001 Sep; 7(9):2757-64. PubMed ID: 11555589 [TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Harbeck N; Alt U; Berger U; Kates R; Krüger A; Thomssen C; Jänicke F; Graeff H; Schmitt M Int J Biol Markers; 2000; 15(1):79-83. PubMed ID: 10763146 [TBL] [Abstract][Full Text] [Related]
10. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Herszényi L; István G; Cardin R; De Paoli M; Plebani M; Tulassay Z; Farinati F Eur J Cancer Prev; 2008 Oct; 17(5):438-45. PubMed ID: 18714186 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cathepsins B and L in primary human breast cancer. Foekens JA; Kos J; Peters HA; Krasovec M; Look MP; Cimerman N; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG J Clin Oncol; 1998 Mar; 16(3):1013-21. PubMed ID: 9508185 [TBL] [Abstract][Full Text] [Related]
12. Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer. Herszènyi L; Plebani M; Carraro P; De Paoli M; Cardin R; Di Mario F; Kusstatscher S; Naccarato R; Farinati F Am J Gastroenterol; 1997 May; 92(5):843-7. PubMed ID: 9149198 [TBL] [Abstract][Full Text] [Related]
13. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075 [TBL] [Abstract][Full Text] [Related]
15. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148 [TBL] [Abstract][Full Text] [Related]
16. The role of urokinase-type plasminogen activator and its inhibitor PAI-1 in gastric cancer. Herszényi L; Plebani M; Cardin R; Carraro P; De Paoli M; Roveroni G; Naccarato R; Farinati F Acta Physiol Hung; 1995; 83(3):213-21. PubMed ID: 8852646 [TBL] [Abstract][Full Text] [Related]
17. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Lah TT; Cercek M; Blejec A; Kos J; Gorodetsky E; Somers R; Daskal I Clin Cancer Res; 2000 Feb; 6(2):578-84. PubMed ID: 10690542 [TBL] [Abstract][Full Text] [Related]
18. [Role and behavior of cathepsin B and cathepsin L in gastric cancer]. Herszényi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Rugge M; Cardin R; Naccarato R; Farinati F Orv Hetil; 1995 Jun; 136(25):1315-8. PubMed ID: 7596589 [TBL] [Abstract][Full Text] [Related]
19. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825 [TBL] [Abstract][Full Text] [Related]
20. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]